JP2011529959A5 - - Google Patents

Download PDF

Info

Publication number
JP2011529959A5
JP2011529959A5 JP2011521666A JP2011521666A JP2011529959A5 JP 2011529959 A5 JP2011529959 A5 JP 2011529959A5 JP 2011521666 A JP2011521666 A JP 2011521666A JP 2011521666 A JP2011521666 A JP 2011521666A JP 2011529959 A5 JP2011529959 A5 JP 2011529959A5
Authority
JP
Japan
Prior art keywords
alkyl
het
oxo
diazocan
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011521666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529959A (ja
JP5530438B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2009/053317 external-priority patent/WO2010015972A1/en
Publication of JP2011529959A publication Critical patent/JP2011529959A/ja
Publication of JP2011529959A5 publication Critical patent/JP2011529959A5/ja
Application granted granted Critical
Publication of JP5530438B2 publication Critical patent/JP5530438B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011521666A 2008-08-06 2009-07-30 Mc4作動薬としてのジアゼピンおよびジアゾカン化合物 Expired - Fee Related JP5530438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8653008P 2008-08-06 2008-08-06
US61/086,530 2008-08-06
PCT/IB2009/053317 WO2010015972A1 (en) 2008-08-06 2009-07-30 Diazepine and diazocane compounds as mc4 agonists

Publications (3)

Publication Number Publication Date
JP2011529959A JP2011529959A (ja) 2011-12-15
JP2011529959A5 true JP2011529959A5 (https=) 2012-09-06
JP5530438B2 JP5530438B2 (ja) 2014-06-25

Family

ID=41226202

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011521666A Expired - Fee Related JP5530438B2 (ja) 2008-08-06 2009-07-30 Mc4作動薬としてのジアゼピンおよびジアゾカン化合物

Country Status (13)

Country Link
US (1) US8592403B2 (https=)
EP (1) EP2326638B9 (https=)
JP (1) JP5530438B2 (https=)
KR (1) KR101280786B1 (https=)
CN (1) CN102171206B (https=)
AU (1) AU2009278838B2 (https=)
CA (1) CA2731897C (https=)
DK (1) DK2326638T5 (https=)
ES (1) ES2421920T3 (https=)
IL (1) IL210703A (https=)
MX (1) MX2011001405A (https=)
WO (1) WO2010015972A1 (https=)
ZA (1) ZA201100374B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512778Y2 (ja) 1990-06-19 1996-10-02 株式会社荏原製作所 全速待機運転ポンプ
ES2402581T3 (es) 2006-02-23 2013-05-06 Pfizer Limited Piperidinoilpirrolidinas como agonistas del receptor de melanocortina tipo 4
CN102464623B (zh) * 2010-11-19 2015-04-29 上海药明康德新药开发有限公司 1,4-二氮杂环辛烷-6-甲酸酯衍生物的制备方法
CA2862444A1 (en) 2011-12-29 2013-07-04 Rhythm Metabolic, Inc. Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers
US11116769B2 (en) * 2013-04-11 2021-09-14 Ctc Bio, Inc. Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
MY173159A (en) * 2013-04-11 2019-12-31 Ctc Bio Inc Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer
PL3333165T3 (pl) * 2015-08-04 2019-12-31 Astellas Pharma Inc. Pochodne piperazyny
MA43040A (fr) 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
EP3773897A1 (en) 2018-04-06 2021-02-17 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507249A (de) * 1968-05-31 1971-05-15 Sandoz Ag Verfahren zur Herstellung von 2-Brom-a-ergokryptin
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
US5274143A (en) * 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
WO1995000497A1 (en) * 1993-06-18 1995-01-05 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE69519995T2 (de) * 1994-10-27 2001-08-23 Janssen Pharmaceutica Nv Apolipoprotein-b syntheseinhibitoren
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors
WO1997017973A1 (en) * 1995-11-13 1997-05-22 Smithkline Beecham Corporation Hemoregulatory compounds
CZ45699A3 (cs) * 1996-08-14 1999-05-12 Zeneca Limited Substituované deriváty pyrimidinu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
AU4020897A (en) * 1996-08-17 1998-03-06 Zeneca Limited 3-mercaptopyrrolidines as farnesyl protein transferase inhibitors
US5929077A (en) * 1996-11-08 1999-07-27 Leftheris; Katerina Thioproline-containing inhibitors of farnesyl protein transferase
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
IL141769A0 (en) * 1998-09-11 2002-03-10 Aventis Pharma Sa Azetidine derivatives, preparation and medicines containing them
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US8273713B2 (en) 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
IL157253A0 (en) 2001-02-28 2004-02-19 Merck & Co Inc Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE60215132T2 (de) 2001-02-28 2007-08-23 Merck & Co., Inc. Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten
SK287592B6 (sk) 2001-03-22 2011-03-04 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty, ktoré majú CB1-antagonistickú účinnosť, spôsob ich prípravy a použitie
WO2003027637A2 (en) 2001-09-24 2003-04-03 Oregon Health And Science University Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
WO2003075660A1 (en) 2002-03-06 2003-09-18 Merck & Co., Inc. Method of treatment or prevention of obesity
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
EP1558252B1 (en) 2002-08-02 2007-10-10 Merck & Co., Inc. Substituted furo [2,3-b]pyridine derivatives
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
MY134457A (en) 2002-11-22 2007-12-31 Merck & Co Inc Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
US7151097B2 (en) * 2003-11-07 2006-12-19 Pfizer Inc. Bicyclic pyrazolyl and imidazolyl compounds and uses thereof
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
EP1802307B1 (en) * 2004-10-15 2008-02-27 Glaxo Group Limited Pyrrolidine derivatives as histamine receptors ligands
WO2006104008A1 (ja) * 2005-03-25 2006-10-05 Kissei Pharmaceutical Co., Ltd. ウレア誘導体、それを含有する医薬組成物およびそれらの医薬用途
WO2007015162A1 (en) 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds

Similar Documents

Publication Publication Date Title
JP2011529959A5 (https=)
CA2642922A1 (en) Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
AU2013329552B2 (en) 5-phenoxy-3H-pyrimidin-4-one derivatives and their use as HIV reverse transcriptase inhibitors
RU2012136643A (ru) [5,6]- гетероциклическое соединение
AU2009292931B2 (en) Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases
JP2010524970A5 (https=)
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
RU2005130020A (ru) Производные пиразолопиридина
HRP20231310T1 (hr) Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
RU2014139601A (ru) Ингибиторы серин/треониновых киназ
JP2012501312A5 (https=)
JP2016519096A5 (https=)
JP2007510689A5 (https=)
JP2016514718A5 (https=)
JP2011503150A5 (https=)
JP2019530695A5 (https=)
CA2351725A1 (en) Substituted pyrazoles as p38 kinase inhibitors
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
JP2014516074A5 (https=)
RU2008126398A (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpti)
JP2011509937A5 (https=)
JP2010506850A5 (https=)
JP2013539777A5 (https=)
RU2009121564A (ru) Азаадамантановые производные и способы применения
JP2008525498A5 (https=)